lamda 10-2 driven dg-4 argon light source (Sutter Instrument Company)
90
Structured Review
Sutter Instrument Company
lamda 10-2 driven dg-4 argon light source
Lamda 10 2 Driven Dg 4 Argon Light Source, supplied by Sutter Instrument Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lamda+10-2+driven+dg-4+argon+light+source/lamda+10+2+driven+dg+4+argon+light+source/pm23357789-148-11-15
Average 90 stars, based on 1 article reviews
Lamda 10 2 Driven Dg 4 Argon Light Source, supplied by Sutter Instrument Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lamda+10-2+driven+dg-4+argon+light+source/lamda+10+2+driven+dg+4+argon+light+source/pm23357789-148-11-15
Average 90 stars, based on 1 article reviews
lamda 10-2 driven dg-4 argon light source - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functions. Article Snippet: Store operated calcium entry (SOCE) downstream of T cell receptor (TCR) activation in T lymphocytes has been shown to be mediated mainly through the Calcium Release Activated Calcium (CRAC) channel.. Here, we compared the effects of a novel, potent and selective CRAC current inhibitor, 2,6-Difluoro-N-{5-[4-methyl-1-(5-methyl-thiazol-2-yl)-1,2,5,6-tetrahydro-pyridin-3yl]-pyrazin-2-yl}-benzamide (RO2959), on T cell effector functions with that of a previously reported CRAC channel inhibitor, YM-58483, and a calcineurin inhibitor Cyclosporin A (CsA).. Using both electrophysiological and calcium-based fluorescence measurements, we showed that RO2959 is a potent SOCE inhibitor that blocked an IP3-dependent current in CRAC-expressing RBL-2H3 cells and CHO cells stably expressing human Orai1 and Stim1, as well as SOCE in human primary CD4+ T cells triggered by either TCR stimulation or thapsigargin treatment. |